BDTX Stock Surges 51%: Unlocking Growth Potential with Silevertinib
Explore how Black Diamond Therapeutics’ 51.1% stock surge, driven by silevertinib’s clinical progress, signals promising growth in oncology investing. Discover key insights and risks shaping BDTX’s future.